University Of Mississippi Medical
- Type
- Teaching hospital
- Where
- JACKSON, MS
- Medicare CCN
- 250001
- Received
- $2,053,737 in 660 records, 2023 ($501,159 general, $1,552,577 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2023 | General payment | 130 | $501,159 |
| 2023 | Research payment | 530 | $1,552,577 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 530 | $1,552,577 |
| Grant | 25 | $210,278 |
| Space rental or facility fees (teaching hospital only) | 67 | $117,408 |
| Long term medical supply or device loan | 15 | $100,529 |
| Education | 6 | $31,500 |
| Debt forgiveness | 8 | $20,356 |
| Royalty or License | 2 | $9,991 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 2 | $6,618 |
| Consulting Fee | 2 | $3,712 |
| Gift | 1 | $725 |
| Food and Beverage | 2 | $40 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2023-12-31 | Merck Sharp & Dohme LLC | $32,130 | Research payment | Cash or cash equivalent | VERQUVO Drug, CARDIOVASCULAR | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulato | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $29,131 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $26,147 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $25,594 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment | 2023 |
| 2023-12-31 | AstraZeneca Pharmaceuticals LP | $25,563 | Research payment | In-kind items and services | ENHERTU Biological, Oncology | Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $17,071 | Research payment | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulato | 2023 |
| 2023-12-31 | Intuitive Surgical, Inc. | $16,988 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $13,831 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A PHASE III RANDOMIZED, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB MK-3475, NSC #776864 IN ADDITION TO PACLITAXEL AND CAR | 2023 |
| 2023-12-31 | Mindray DS USA, Inc. | $7,125 | Long term medical supply or device loan | In-kind items and services | TE X Device, ULTRASOUND | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $5,457 | Research payment | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulato | 2023 |
| 2023-12-31 | Intuitive Surgical, Inc. | $5,000 | Education | In-kind items and services | DAVINCI XI Device, SURGERY | 2023 | |
| 2023-12-31 | Stryker Corporation | $4,656 | Long term medical supply or device loan | In-kind items and services | CORE, MAESTRO Device, NEURO SPINE ENT | 2023 | |
| 2023-12-31 | Stryker Corporation | $3,583 | Long term medical supply or device loan | In-kind items and services | CHROMOPHARE F300 Device, COMMUNICATIONS | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $3,552 | Research payment | In-kind items and services | LAGEVRIO Biological, INFECTIOUS DISEASE | A Phase 2,3 Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety and Pharmacokin | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $3,552 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A PHASE III RANDOMIZED, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB MK-3475, NSC #776864 IN ADDITION TO PACLITAXEL AND CAR | 2023 |
| 2023-12-31 | Intuitive Surgical, Inc. | $3,427 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | 2023 | |
| 2023-12-31 | Stryker Corporation | $2,305 | Long term medical supply or device loan | In-kind items and services | PRIME SERIES Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $1,085 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment | 2023 |
| 2023-12-31 | Philips North America LLC | $1,020 | Long term medical supply or device loan | In-kind items and services | (8269) DreamStation Cpap Device, Medical Device | 2023 | |
| 2023-12-31 | Medline Industries LP | $814 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-12-31 | Philips North America LLC | $800 | Long term medical supply or device loan | In-kind items and services | (2747) Actiwatch Device, Medical Device | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $281 | Research payment | In-kind items and services | JANUVIA Drug, ENDOCRINOLOGY | A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficac | 2023 |
| 2023-12-31 | AstraZeneca UK Limited | $270 | Research payment | In-kind items and services | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclon | 2023 | |
| 2023-12-31 | Stryker Corporation | $142 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-12-31 | Merck Sharp & Dohme LLC | $107 | Research payment | In-kind items and services | ZERBAXA Drug, INFECTIOUS DISEASE | A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PHASE 3 STUDY TO ASSESS THE SAFETY AND EFFICACY OF INTRAVENOUS CEF | 2023 |
| 2023-12-31 | Stryker Corporation | $95 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-12-31 | Merck Sharp & Dohme LLC | $62 | Research payment | Cash or cash equivalent | JANUMET Drug, ENDOCRINOLOGY | A Phase III Multicenter, Double-Blind, Randomized Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $38 | Research payment | Cash or cash equivalent | JANUVIA Drug, ENDOCRINOLOGY | A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficac | 2023 |
| 2023-12-31 | Stryker Corporation | $38 | Long term medical supply or device loan | In-kind items and services | MISTRAL-AIR Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-28 | ABBVIE INC. | $1,045 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allog | 2023 |
| 2023-12-27 | GE HEALTHCARE | $69,572 | Research payment | Cash or cash equivalent | 2023 | ||
| 2023-12-27 | E.R. Squibb & Sons, L.L.C. | $4,000 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase IIA Nivo in HL Pediatric (nivo+bv) - A Phase I/II Trial of Nivolumab Plus Ipilimumab in Children and Young Adults | 2023 |
| 2023-12-27 | United Therapeutics Corporation | $2,978 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2023 |
| 2023-12-25 | Janssen Research & Development, LLC | $958 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D | 2023 |
| 2023-12-22 | Genentech, Inc. | $473 | Research payment | Cash or cash equivalent | AN OPEN LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLE | 2023 | |
| 2023-12-21 | Medical Device Business Services, Inc. | $131 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Attune Revision RTKA Population Multi Center Clinical Evaluation of the Attune Revision System in Complex Primary Total | 2023 |
| 2023-12-20 | Synthes GmbH | $10,000 | Grant | Cash or cash equivalent | 2023 | ||
| 2023-12-19 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-12-18 | Janssen Research & Development, LLC | $2,117 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D | 2023 |
| 2023-12-18 | Novo Nordisk AS | $1,821 | Research payment | Cash or cash equivalent | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-12-15 | Janssen Research & Development, LLC | $9,760 | Research payment | Cash or cash equivalent | PREZISTA Drug, Infectious Diseases & Vaccines | A Phase 4 Randomized Active Controlled Open label Study to Evaluate the Safety and Tolerability of Switching to Once Dai | 2023 |
| 2023-12-13 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-12-12 | United Therapeutics Corporation | $6,104 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2023 |
| 2023-12-12 | Applied Therapeutics, inc. | $3,714 | Research payment | Cash or cash equivalent | Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy | 2023 | |
| 2023-12-12 | United Therapeutics Corporation | $2,475 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2023 |
| 2023-12-12 | United Therapeutics Corporation | $2,000 | Research payment | Cash or cash equivalent | REMODULIN Drug, PAH | INTRAVENOUS REMODULIN (TREPROSTINIL) AS ADD-ON THERAPY FOR THE TREATMENT OF PERSISTENT PULMONARY HYPERTENSION OF THE NEW | 2023 |
| 2023-12-12 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-12-12 | United Therapeutics Corporation | $199 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2023 |
| 2023-12-11 | LivaNova USA, Inc. | $44,179 | Research payment | Cash or cash equivalent | VNS - Vitaria Device, Cardiology/Vascular Diseases | ANTHEM HFrEF | 2023 |
| 2023-12-11 | Janssen Research & Development, LLC | $6,250 | Research payment | Cash or cash equivalent | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Co | 2023 | |
| 2023-12-11 | Janssen Research & Development, LLC | $6,250 | Research payment | Cash or cash equivalent | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Co | 2023 | |
| 2023-12-08 | Stryker Corporation | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | NA Device, TRAUMA & EXTREMETIES | 2023 | |
| 2023-12-08 | Stryker Corporation | $4,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | NA Device, TRAUMA & EXTREMETIES | 2023 | |
| 2023-12-08 | Stryker Corporation | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | NA Device, TRAUMA & EXTREMETIES | 2023 | |
| 2023-12-06 | Synthes GmbH | $6,000 | Grant | Cash or cash equivalent | 2023 | ||
| 2023-12-05 | ARGENX US, INC. | $15,004 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Immunology | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety | 2023 |
| 2023-12-01 | Boston Scientific Corporation | $2,000 | Grant | In-kind items and services | Device, General - Interventional Oncology_PI | 2023 | |
| 2023-11-29 | Stryker Corporation | $5,000 | Grant | Cash or cash equivalent | 2023 | ||
| 2023-11-28 | W. L. Gore & Associates, Inc. | $74,167 | Grant | Cash or cash equivalent | GORE-TEX Vascular Graft Device, Devices | 2023 | |
| 2023-11-27 | Bayer Healthcare Pharmaceuticals Inc. | $614 | Research payment | Cash or cash equivalent | Kerendia Drug, Cardio-renal | BAY94-8862 LCM HFmr/pEF (EF 40%) | 2023 |
| 2023-11-22 | Stryker Corporation | $1,272 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | VSP SYSTEM, VSP CRANIAL Device, CRANIOMAXILLOFACIAL | 2023 | |
| 2023-11-20 | ABBVIE INC. | $25,000 | Grant | Cash or cash equivalent | 2023 | ||
| 2023-11-16 | Stryker Corporation | $1,166 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | MEDPOR Device, MEDPOR | 2023 | |
| 2023-11-16 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-11-16 | ABBVIE INC. | $150 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allog | 2023 |
| 2023-11-16 | Novo Nordisk AS | $70 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-16 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-11-15 | Ivoclar Vivadent, Inc. | $2,728 | Research payment | In-kind items and services | 2023 | ||
| 2023-11-10 | Janssen Research & Development, LLC | $8,339 | Research payment | Cash or cash equivalent | STELARA Biological, Immunology | A Phase 3b Randomized Double blind Multi Center Study to Evaluate the Safety and Efficacy of Intravenous Reinduction The | 2023 |
| 2023-11-10 | GlaxoSmithKline, LLC. | $756 | Research payment | Cash or cash equivalent | AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD | 2023 | |
| 2023-11-10 | Medical Device Business Services, Inc. | $491 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Multi Center Clinical Evaluation of the ATTUNE Revision System in Revision Total Knee Arthroplasty | 2023 |
| 2023-11-09 | Janssen Research & Development, LLC | $1,911 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D | 2023 |
| 2023-11-07 | Bayer Healthcare Pharmaceuticals Inc. | $5,140 | Research payment | Cash or cash equivalent | Kerendia Drug, Cardio-renal | BAY94-8862, Finerenone Phase 3 in non-diabetic CKD | 2023 |
| 2023-11-07 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-11-03 | Ethicon US, LLC | $3,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | VISTASEAL Biological, Biosurgical | 2023 | |
| 2023-10-31 | CSL Behring | $15,000 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2023 |
| 2023-10-31 | CSL Behring | $1,500 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2023 |
| 2023-10-31 | CSL Behring | $1,000 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2023 |
| 2023-10-25 | KLS-Martin L.P. | $2,500 | Grant | Cash or cash equivalent | 2023 | ||
| 2023-10-23 | DePuy Synthes Sales Inc. | $10,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | TRUMATCH Device, Ortho-Knee | 2023 | |
| 2023-10-23 | Bayer Healthcare Pharmaceuticals Inc. | $9,120 | Research payment | Cash or cash equivalent | Kerendia Drug, Cardio-renal | BAY94-8862, Finerenone Phase 3 in non-diabetic CKD | 2023 |
| 2023-10-23 | ABBVIE INC. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | BOTOX Biological, BOTOX THERAPEUTIC | 2023 | |
| 2023-10-20 | Stryker Corporation | $880 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | N/A Device, NAVIGATION | 2023 | |
| 2023-10-20 | Stryker Corporation | $220 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | N/A Device, NAVIGATION | 2023 | |
| 2023-10-18 | Acera Surgical, Inc. | $10,000 | Education | Cash or cash equivalent | 2023 | ||
| 2023-10-18 | TAIHO ONCOLOGY, INC. | $4,500 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label, Non-Randomized, Safety, Tolerability and Pharmacokinetic Study of TAS3681 in Patients With Metast | 2023 | |
| 2023-10-18 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-10-17 | United Therapeutics Corporation | $4,075 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2023 |
| 2023-10-17 | United Therapeutics Corporation | $3,278 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2023 |
| 2023-10-17 | United Therapeutics Corporation | $2,680 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2023 |
| 2023-10-13 | Apellis Pharmaceuticals, Inc. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Syfovre Drug, Ophthalmology | 2023 | |
| 2023-10-11 | KLS-Martin L.P. | $7,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2023 | ||
| 2023-10-11 | KLS-Martin L.P. | $2,500 | Grant | Cash or cash equivalent | 2023 | ||
| 2023-10-09 | GLOBAL BLOOD THERAPEUTICS, INC. | $3,271 | Research payment | Cash or cash equivalent | OXBRYTA Drug, HEMATOLOGY | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF VOXELOTOR GBT440 IN PEDIATRIC PARTICIPANTS WITH SICKLE CELL | 2023 |
| 2023-10-04 | Novo Nordisk Inc | $2,250 | Research payment | Cash or cash equivalent | Wegovy Drug, Obesity | EX9536-4665 | 2023 |
| 2023-10-02 | Janssen Research & Development, LLC | $3,623 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D | 2023 |
| 2023-10-02 | Janssen Research & Development, LLC | $1,592 | Research payment | Cash or cash equivalent | PREZISTA Drug, Infectious Diseases & Vaccines | A Phase 4 Randomized Active Controlled Open label Study to Evaluate the Safety and Tolerability of Switching to Once Dai | 2023 |
| 2023-09-30 | Intuitive Surgical, Inc. | $16,988 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | 2023 | |
| 2023-09-30 | Intuitive Surgical, Inc. | $5,000 | Education | In-kind items and services | DAVINCI XI Device, SURGERY | 2023 | |
| 2023-09-30 | Intuitive Surgical, Inc. | $3,427 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | 2023 | |
| 2023-09-30 | Inari Medical, Inc. | $2,161 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PEERLESS STUDY | 2023 |
| 2023-09-30 | Inari Medical, Inc. | $1,355 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PEERLESS STUDY | 2023 |
| 2023-09-30 | Inari Medical, Inc. | $1,100 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PEERLESS STUDY | 2023 |
| 2023-09-30 | Inari Medical, Inc. | $1,100 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PEERLESS STUDY | 2023 |
| 2023-09-30 | Inari Medical, Inc. | $1,015 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PEERLESS STUDY | 2023 |
| 2023-09-30 | Inari Medical, Inc. | $903 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PEERLESS STUDY | 2023 |
| 2023-09-30 | Inari Medical, Inc. | $903 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PEERLESS STUDY | 2023 |
| 2023-09-30 | Inari Medical, Inc. | $903 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PEERLESS STUDY | 2023 |
| 2023-09-29 | W. L. Gore & Associates, Inc. | $982 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | GREAT Global Registry for Endovascular Aortic Treatment | 2023 |
| 2023-09-27 | Octapharma USA, Inc. | $500 | Research payment | Cash or cash equivalent | BALFAXAR Biological, Intensive Care/Emergency | LEX-210 | 2023 |
| 2023-09-26 | Mentor Worldwide LLC | $10,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | MENTOR MemoryGel Resterilizable Gel Sizer Device, Plastic Surgery | 2023 | |
| 2023-09-26 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-09-25 | Medtronic, Inc. | $785 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2023 |
| 2023-09-22 | Medtronic, Inc. | $8,000 | Grant | Cash or cash equivalent | 2023 | ||
| 2023-09-22 | National Marrow Donor Program | $5,500 | Research payment | Cash or cash equivalent | 1/2A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy fo | 2023 | |
| 2023-09-22 | Boston Scientific Corporation | $1,500 | Grant | In-kind items and services | Device, General - Structural Heart_IC | 2023 | |
| 2023-09-21 | Medical Device Business Services, Inc. | $150 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Multi Center Clinical Evaluation of the ATTUNE Revision System in Revision Total Knee Arthroplasty | 2023 |
| 2023-09-20 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-09-15 | ABBVIE INC. | $45 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis | 2023 |
| 2023-09-14 | Applied Therapeutics, inc. | $3,562 | Research payment | Cash or cash equivalent | Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy | 2023 | |
| 2023-09-13 | Merck Sharp & Dohme LLC | $10,778 | Research payment | Cash or cash equivalent | WELIREG Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel | 2023 |
| 2023-09-13 | Takeda Pharmaceuticals U.S.A., Inc. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2023 | ||
| 2023-09-07 | Synthes GmbH | $30,000 | Grant | Cash or cash equivalent | 2023 | ||
| 2023-09-06 | United Therapeutics Corporation | $4,500 | Research payment | Cash or cash equivalent | REMODULIN Drug, PAH | INTRAVENOUS REMODULIN (TREPROSTINIL) AS ADD-ON THERAPY FOR THE TREATMENT OF PERSISTENT PULMONARY HYPERTENSION OF THE NEW | 2023 |
| 2023-08-29 | ABBVIE INC. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | DURYSTA Drug, EYE CARE | 2023 | |
| 2023-08-28 | Janssen Research & Development, LLC | $779 | Research payment | Cash or cash equivalent | STELARA Biological, Immunology | A Phase 3b Randomized Double blind Multi Center Study to Evaluate the Safety and Efficacy of Intravenous Reinduction The | 2023 |
| 2023-08-24 | Genentech, Inc. | $1,322 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | Ph 3 study of glofitamab with GemOx vs rituximab with GemOx in patients with R R DLBCL | 2023 |
| 2023-08-24 | Bayer Healthcare Pharmaceuticals Inc. | $1,075 | Research payment | Cash or cash equivalent | Kerendia Drug, Cardio-renal | BAY94-8862 LCM HFmr/pEF (EF 40%) | 2023 |
| 2023-08-24 | E.R. Squibb & Sons, L.L.C. | $1,000 | Research payment | Cash or cash equivalent | SPRYCEL Drug, Oncology | Phase II Pediatric Ph+ ALL - A Phase 2 Multi-Center, Historically-Controlled Study of Dasatinib Added to Standard Chemot | 2023 |
| 2023-08-19 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-08-18 | Novo Nordisk AS | $1,347 | Research payment | Cash or cash equivalent | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-08-17 | Merck Sharp & Dohme LLC | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | PREVYMIS Drug, INFECTIOUS DISEASE | 2023 | |
| 2023-08-17 | Veloxis Pharmaceuticals, Inc. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ENVARSUS Drug, TRANSPLANTATION | 2023 | |
| 2023-08-17 | Regeneron Healthcare Solutions, Inc. | $1,500 | Grant | Cash or cash equivalent | EYLEA Biological, OPHTHALMOLOGY | 2023 | |
| 2023-08-16 | E.R. Squibb & Sons, L.L.C. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2023 | |
| 2023-08-14 | Abbott Laboratories | $300 | Research payment | Cash or cash equivalent | XIENCE SIERRA Device, Vascular | A Single Arm, Non-randomized, Multi-center Clinical Study of the SJM Masters HP 15mm Rotatable Mechanical Heart Valve as | 2023 |
| 2023-08-14 | Ivoclar Vivadent, Inc. | $21 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-08-12 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-08-08 | United Therapeutics Corporation | $24,500 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2023 |
| 2023-08-04 | PFIZER INC. | $17,500 | Research payment | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | ELRANATAMAB PF06863135 MONOTHERAPY EXPANDED ACCESS PROTOCOL FOR TREATMENT OF PATIENTS WITH RELAPSEDREFRACTORY MULTIPLE M | 2023 |
| 2023-08-04 | Stryker Corporation | $833 | Grant | Cash or cash equivalent | 2023 | ||
| 2023-08-03 | Galvanize Therapeutics, Inc | $38,427 | Research payment | Cash or cash equivalent | RHEOX Device, PULSED ELECTRIC FIELD | CS006 RheOx Pivotal | 2023 |
| 2023-08-02 | KLS-Martin L.P. | $2,500 | Grant | Cash or cash equivalent | 2023 | ||
| 2023-08-01 | ARGENX US, INC. | $20,500 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Immunology | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety | 2023 |
| 2023-08-01 | ARGENX US, INC. | $1,000 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Immunology | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety | 2023 |
| 2023-07-31 | Novo Nordisk AS | $1,277 | Research payment | Cash or cash equivalent | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-07-28 | Hikma Pharmaceuticals USA | $16,250 | Research payment | Cash or cash equivalent | Phenobarbital Drug, Sleep | Phenobarbital Neonate Study Phase III | 2023 |
| 2023-07-28 | Janssen Pharmaceuticals, Inc | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | XARELTO Drug, Cardiovascular & Metabolism | 2023 |
The latest 200 records of 660.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Jackson, MS, county Hinds County, MS, state Mississippi; placed by its city name.
| Measure | Place (city or town) Jackson, MS | County Hinds County, MS | State Mississippi |
|---|---|---|---|
| Population B01003 | 146,631 | 218,533 | 2,946,779 |
| Population, 2020 census P1 | 153,701 | 227,742 | 2,961,279 |
| Median age B01002 | 34.5 | 36.9 | 38.6 |
| Under 18 B01001 | 23.9% | 23.5% | 23.3% |
| 65 and over B01001 | 15.0% | 16.3% | 17.2% |
| Households B11001 | 61,415 | 89,578 | 1,145,431 |
| Foreign born B05002 | 1.6% | 2.0% | 2.4% |
| Median household income B19013 | $42,071 | $49,402 | $56,447 |
| Median family income B19113 | $52,810 | $64,969 | $73,163 |
| Per capita income B19301 | $26,811 | $29,530 | $31,549 |
| Poverty rate B17001 | 27.9% | 22.7% | 18.9% |
| Unemployment rate B23025 | 9.3% | 7.5% | 5.8% |
| Civilian labor force B23025 | 69,393 | 102,828 | 1,332,121 |
| Mean commute (minutes) B08013 | 19.9 | 22.3 | 25.6 |
| Bachelor's degree or higher B15003 | 28.8% | 31.2% | 25.1% |
| Housing units B25001 | 74,871 | 106,340 | 1,341,114 |
| Owner-occupied B25003 | 48.6% | 58.3% | 70.0% |
| Renters B25003 | 51.4% | 41.7% | 30.0% |
| Median home value B25077 | $111,700 | $159,900 | $169,800 |
| Median gross rent B25064 | $1,055 | $1,061 | $954 |
| White, not Hispanic B03002 | 13.3% | 22.9% | 55.2% |
| Black B03002 | 81.7% | 71.7% | 36.3% |
| Hispanic or Latino B03002 | 2.4% | 2.1% | 3.7% |
| Asian B03002 | 0.3% | 0.8% | 1.0% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.4% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Jackson, MS.
Comments